RxDoctor Payments Data

Matthew Dangleis, PA

Physician Assistant · Bellingham, WANPI 1033887575

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $4,745 of the $7,906 with a category attached, or 60.0%. 11 manufacturers reported payments, led by Boston Scientific at 29.8% of the total. Reporting peaked in 2023 at $4,333 and has fallen 68.9% since, to $1,348 in 2025. Among physician assistant clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,906in general payments, 2019–2025

Across 147 payments — averaging $53.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Abbott$2K
  • Nevro Corp.$2K
  • Relievant Medsystems, Inc.$1K
  • Saluda Medical Americas, Inc.$280
  • Collegium Pharmaceutical, Inc.$196
  • plus $313 from 5 others

What the payments were for

  • Speaking & faculty fees$2703%
  • Travel & lodging$4,74560%
  • Food & beverage$2,89137%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,906 in reported general payments places this provider in the 95th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$184,666
Medicare patients
300
Services billed
7,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate64$25,579
BelbucaBuprenorphine Hcl39$18,483
OxycontinOxycodone Hcl23$11,200
Oxycodone Hcl531$10,039
Fentanyl103$9,525
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen373$9,073
Buprenorphine45$8,767
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen185$4,883
Morphine Sulfate ErMorphine Sulfate139$3,871
Celecoxib223$3,062
Methadone Hcl98$2,727
Morphine Sulfate45$1,460
Pregabalin89$1,309
Lidocaine17$1,296
Tramadol Hcl ErTramadol Hcl27$1,239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$196$44,062103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Bellingham

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →